Bayer's Off-Label Yaz Marketing Violated FCA: Watchdog
By Sindhu Sundar · December 14, 2011, 4:57 PM EST
A pharmaceutical company watchdog accused Bayer Schering Pharma AG of marketing its Yasmin and Yaz contraceptives for unapproved purposes and causing doctors to seek Medicaid reimbursements for off-label prescriptions of those...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login